A retrospective review of 77 SoJIA patients revealed that 50-70% achieved inactive disease or remission when treated with IL-1 inhibitors (anakinra, canakinumab). Good responses were seen with tocilizumab or abatacept, but only 8% responded to etanercept. With up to 8 years of followup, a significant degree of biologic switching was observed. Complete remission was achieved in more than half of patients. Numerous (24) serious adverse events were seen, including numerous infections, macrophage activation syndrome, ANCA+ glomerulonephritis and Crohn’s colitis.